Eliciting Mucosal Immunity to Tuberculosis (EMI-TB)

Project leader

Funding source

EU Horizon 2020

Project Details

Start date: 01/01/2015
End date: 31/12/2018
Funding: 7999920 EUR


Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine,Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against thepulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latentMycobacterium tuberculosis (MTB) infection. Effective prophylactic vaccination remains the key long-term strategy forcombating TB. Continued belief in reaching this goal requires unrelenting innovation in the formulation and delivery ofcandidate vaccines. It is also based on the assumption, that the failure of recent human vaccine trials could have been dueto a sub-optimal vaccine design and delivery, and therefore should not erode the key principle that a TB vaccine is anattainable target. This proposal focuses on mucosal vaccination, which has been considered in the past, but notimplemented efficiently. The innovation of the proposal is focused on several important aspects of vaccine development andtesting, including the use of novel technologies for vaccine delivery, novel ways of specific targeting of mucosal immune cellsand tissues, the use of polypeptides incorporating early and latent MTB antigens and putative CD8+ T cell epitopes, andapplication of novel tools for identifying early predictors and correlates of vaccine-induced protection. The overall objective isto design a vaccine that will induce a broad-ranging immune response to MTB both systemically and in the mucosa of thelungs, and provide the currently missing links in protective immunity to this pathogen.

External Partners

Last updated on 2018-11-12 at 09:58